Closing the Gap: the Real-World Risk of Serious Infections With Vedolizumab in Comparison With Anti-TNF Therapy in Inflammatory Bowel Disease

Clin Gastroenterol Hepatol. 2022 Feb;20(2):e28-e30. doi: 10.1016/j.cgh.2021.05.026. Epub 2021 May 20.

Authors

Waseem Ahmed¹, Frank I Scott²

Affiliations

¹ Jill Roberts Center for Inflammatory Bowel Disease, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, New York, New York.
² Crohn's and Colitis Center, Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

PMID: 34022455
DOI: 10.1016/j.cgh.2021.05.026

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Humans
Inflammatory Bowel Diseases* / drug therapy
Tumor Necrosis Factor Inhibitors*

Substances

Antibodies, Monoclonal, Humanized
Tumor Necrosis Factor Inhibitors
vedolizumab